Rating Change
B. Riley Securities reiterated its Buy rating on MiNK Therapeutics, Inc. (NASDAQ:INKT) on October 21, 2026.
reiterateNASDAQ:INKT
B. Riley Securities Reiterates Buy Rating on MiNK Therapeutics, Inc. (INKT)
B. Riley Securities reiterated its Buy rating on MiNK Therapeutics, Inc.
At publication ·
What changed
MiNK Therapeutics, Inc. (NASDAQ:INKT) · reiterate
- Firm
- B. Riley Securities
- Rating
- Buy to Buy
- Price at event
- $10.00
- Market capitalization
- $58.3M
At a glance
Key takeaways
- B. Riley Securities reiterated a Buy rating on MiNK Therapeutics (INKT) on October 21, 2026, with the stock trading at $10.00 and a market cap of $58.3 million.
Market Context
MiNK Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $10.00 with a market capitalization of $58.3M. The stock has declined 29.6% over the past 52 weeks.
Analyst coverage from B. Riley Securities provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for MiNK Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for MiNK Therapeutics, Inc.
Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 21, 2026 | B. Riley Securities | Buy | N/A |
| May 18, 2026 | HC Wainwright & Co. | Buy | N/A |
| Apr 01, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 15, 2025 | HC Wainwright & Co. | Buy | N/A |
| Jul 15, 2025 | HC Wainwright & Co. | Neutral | N/A |
Related Tools: Analyst Ratings Dashboard | View INKT Stock Page
Frequently Asked Questions
What does the Buy rating mean for INKT?
A rating of Buy from B. Riley Securities reflects the analyst's outlook on MiNK Therapeutics, Inc. (NASDAQ:INKT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the INKT forecast page.